Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Mobic (China vs Germany) in Healthy Volunteers
NCT02183142Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2001
- Primary completion
- Apr 2001
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of meloxicam in osteoarthritis (OA) and rheumatoid arthritis (RA) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum measured concentration of the analyte in plasma up to 96 hours and Area under the concentration-time curve from time zero to infinity up to 96 hours. Started Mar 2001; status: completed.
02
Drugs
meloxicam
03
Conditions
osteoarthritis (OA)rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02183142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02183142.